dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Hack, Stephen |
dc.contributor.author | Verret, Wendy |
dc.contributor.author | Mulla, Sohail |
dc.contributor.author | Liu, Bo |
dc.contributor.author | Wang, Yulei |
dc.contributor.author | Macarulla Mercadé, Teresa |
dc.date.accessioned | 2022-06-20T08:39:53Z |
dc.date.available | 2022-06-20T08:39:53Z |
dc.date.issued | 2021-07-31 |
dc.identifier.citation | Hack SP, Verret W, Mulla S, Liu B, Wang Y, Macarulla T, et al. IMbrave 151: a randomized phase II trial of atezolizumab combined with bevacizumab and chemotherapy in patients with advanced biliary tract cancer. Ther Adv Med Oncol. 2021 Jul 31;13:1–17. |
dc.identifier.issn | 1758-8359 |
dc.identifier.uri | https://hdl.handle.net/11351/7719 |
dc.description | Càncer del tracte biliar; Immunoteràpia contra el càncer; Colangiocarcinoma |
dc.description.sponsorship | The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: The study is funded by F. Hoffmann-La Roche Ltd. |
dc.language.iso | eng |
dc.publisher | SAGE Publications |
dc.relation.ispartofseries | Therapeutic Advances in Medical Oncology;13 |
dc.rights | Attribution-NonCommercial 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by-nc/4.0/ |
dc.source | Scientia |
dc.subject | Tracte biliar - Càncer - Tractament |
dc.subject | Quimioteràpia combinada |
dc.subject | Avaluació de resultats (Assistència sanitària) |
dc.subject.mesh | Biliary Tract Neoplasms |
dc.subject.mesh | /drug therapy |
dc.subject.mesh | Antineoplastic Combined Chemotherapy Protocols |
dc.subject.mesh | Progression-Free Survival |
dc.title | IMbrave 151: a randomized phase II trial of atezolizumab combined with bevacizumab and chemotherapy in patients with advanced biliary tract cancer |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.1177/17588359211036544 |
dc.subject.decs | neoplasias del tracto biliar |
dc.subject.decs | /farmacoterapia |
dc.subject.decs | protocolos de quimioterapia antineoplásica combinada |
dc.subject.decs | supervivencia libre de progresión |
dc.relation.publishversion | https://doi.org/10.1177/17588359211036544 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [Hack SP] Genentech, Inc, 1 DNA Way, South San Francisco, USA. [Verret W] Genentech, South San Francisco, CA, USA. [Mulla S] Hoffmann-La Roche Limited, Mississauga, ON, Canada. [Liu B] Genentech, South San Francisco, CA, USA. [Wang Y] Genentech, South San Francisco, CA, USA. [Macarulla T] Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain |
dc.identifier.pmid | 34377158 |
dc.identifier.wos | 000688606800001 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |